Magnesium interrelationships in ischemic heart disease: a review

Mildred S. Seelig, M.D., M.P.H., and H. Alexander Heggtveit, M.D.

Magnesium ions are essential for the maintenance of the functional and structural integrity of the myocardium. Experimental magnesium deficiency induces cardiac necrosis and enhances susceptibility to cardiotoxic agents; magnesium administration is protective. Recent investigations indicate that cellular loss of magnesium may be a basic biochemical mechanism in the evolution of myocardial lesions of diverse etiology. Other studies have shown that magnesium depletion influences coronary flow, blood clotting, and atherogenesis. This paper surveys the cardiovascular role of magnesium as it relates to certain facets of ischemic heart disease.

Loss of myocardial magnesium from ischemic hearts; anoxic hearts

Laboratory models. Magnesium loss from the myocardium is one of the earliest changes found in several cardiomyopathic animal models (1, 2), including production of cardiac hypoxia by coronary ligation, by asphyxia, or by hemorrhagic hypotension (Table 1). The time lag after induction of hypoxia influences the degree of magnesium loss from the myocardial muscle. Cummings (3) and Cummings and Clark (4) first demonstrated loss of myocardial Mg (by 1 hr after a two-stage coronary ligation). Rigo et al. (5) found less loss of myocardial Mg in hearts analyzed 6 days after coronary ligation. Jennings (6) and Jennings and Shen (7) found that 40 min after temporary ligation there was almost one-third loss of myocardial Mg, which is not seen in hearts of dogs 1 hr after permanent ligation. Hochrein and co-workers’ (8) study of hearts from guinea pigs in anoxic chambers demonstrated an early drop in magnesium that was followed by a rise. Dogs with myocardial hypoxia secondary to hemorrhagic hypotension had increased losses of myocardial Mg from 135 to 180 min after the bleeding (9).

Human material. Ventricular muscle of patients who died of myocardial infarcts, reported by Iseri et al. (10), Meister and Schumann (11), Raab (12, 13) and Heggtveit et al. (14), had significantly lower magnesium content, particularly of the infarcted portion of the heart, as compared with magnesium levels in noninfarcted segments, and in hearts of patients who died of other causes (Table 2). In the study of Heggtveit et al. (14), hearts obtained at autopsy within 2 hr of death were examined grossly and microscopically. Mg was assayed in samples of left ventricular muscle by atomic absorption spectrophotometry. The mean myocardial Mg content of normal hearts from sudden traumatic deaths was 85.44 mEq/kg dry weight. Acutely infarcted heart muscle showed a 42% average decrease in Mg content, whereas the noninfarcted areas of the same hearts showed a 19% decrease. This latter diminution was comparable to that found in cases of sudden coronary death without detectable infarction. Skeletal muscle Mg levels did not differ significantly between the control and coronary groups. Laurendeau and DuRuisseau (15) re-
Coronary ligation (dogs)
Cummings and Clark (4)
Cummings (3)
Rigo et al. (5)
Jennings (6); Jennings and Shen (7)
Asphyxia (guinea pigs)
Hochrein et al. (8)

Infarcted tissue:
Infarcted ventricle: 30% ↓ (vs noninfarcted)
Noninfarcted ventricle: 49% ↓ (vs sham-operated heart)

Necrotic area: 21% ↓ (vs intact area)
Perinecrotic area: 9% ↓

Jennings (6); Jennings and Shen (7)
40 min, then reflow 60 min

29% ↓ (vs control heart)
1% ↓ (vs control heart)

Hemorrhagic hypotension (dogs)
Canepa et al. (9)

Duration, min
0.5
1.0–1.5
2.0
2.5–4.0
8.0
10.0
10.5

15% ↓ vs control
31% ↓ vs control
33% ↓ vs control
34% ↓ vs control
30% ↓ vs control
25% ↓ vs control
7% ↓ vs control

Myocardial magnesium

<table>
<thead>
<tr>
<th>TABLE 1</th>
<th>Loss of myocardial magnesium in cardiac hypoxia (laboratory models)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coronary ligation (dogs)</td>
<td>After ligation 8–11 hr Infarcted tissue: 30% ↓ (vs noninfarcted)</td>
</tr>
<tr>
<td>Cummings and Clark (4)</td>
<td>Infarcted ventricle: 49% ↓ (vs sham-operated heart)</td>
</tr>
<tr>
<td>Cummings (3)</td>
<td>Noninfarcted ventricle: 7% ↓</td>
</tr>
<tr>
<td>Rigo et al. (5)</td>
<td>6 days Necrotic area: 21% ↓ (vs intact area)</td>
</tr>
<tr>
<td>Jennings (6); Jennings and Shen (7)</td>
<td>40 min, then reflow 60 min</td>
</tr>
<tr>
<td></td>
<td>29% ↓ (vs control heart)</td>
</tr>
<tr>
<td></td>
<td>1% ↓ (vs control heart)</td>
</tr>
<tr>
<td>Asphyxia (guinea pigs)</td>
<td>Duration, min</td>
</tr>
<tr>
<td>Hochrein et al. (8)</td>
<td>0.5</td>
</tr>
<tr>
<td></td>
<td>15% ↓ vs control</td>
</tr>
<tr>
<td></td>
<td>1.0–1.5</td>
</tr>
<tr>
<td></td>
<td>31% ↓ vs control</td>
</tr>
<tr>
<td></td>
<td>2.0</td>
</tr>
<tr>
<td></td>
<td>33% ↓ vs control</td>
</tr>
<tr>
<td></td>
<td>2.5–4.0</td>
</tr>
<tr>
<td></td>
<td>34% ↓ vs control</td>
</tr>
<tr>
<td></td>
<td>8.0</td>
</tr>
<tr>
<td></td>
<td>30% ↓ vs control</td>
</tr>
<tr>
<td></td>
<td>10.0</td>
</tr>
<tr>
<td></td>
<td>25% ↓ vs control</td>
</tr>
<tr>
<td></td>
<td>10.5</td>
</tr>
<tr>
<td></td>
<td>7% ↓ vs control</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TABLE 2</th>
<th>Loss of myocardial magnesium in cardiac ischemia (human)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myocardial infarcts</td>
<td>Percentage decrease in myocardial magnesium (from control, noninfarcted hearts: autopsy)</td>
</tr>
<tr>
<td>Iseri et al. (10)</td>
<td>Infarcted segment 42 ↓</td>
</tr>
<tr>
<td></td>
<td>Noninfarcted segment 33 ↓</td>
</tr>
<tr>
<td>Meister and Schumann (11)</td>
<td>Infarcted heart 19 ↓</td>
</tr>
<tr>
<td>Raab and Kimura (12, 13)</td>
<td>Noninfarcted segment 32 ↓</td>
</tr>
<tr>
<td>Heggtevit et al. (14)</td>
<td>Infarcted segment 42 ↓</td>
</tr>
<tr>
<td></td>
<td>Noninfarcted segment 19 ↓</td>
</tr>
<tr>
<td>Carbon monoxide poisoning</td>
<td>23 ↓</td>
</tr>
<tr>
<td>Laurendeau and DuRuisseau (15)</td>
<td></td>
</tr>
<tr>
<td>DuRuisseau (16)</td>
<td></td>
</tr>
<tr>
<td>Induced cardiac arrest in surgery</td>
<td></td>
</tr>
<tr>
<td>Cardiac surgery</td>
<td>Myocardial biopsy 2–19 ↓</td>
</tr>
</tbody>
</table>

Changes in plasma magnesium after myocardial infarction

Patients with myocardial infarcts who were admitted to a hospital have been reported to have lowered serum magnesium levels by three groups of investigators (18–20) and to have levels not significantly different from controls by two (21, 22). Holtmeier (18) and Hughes and Tonks (19) took blood from acute myocardial infarct patients shortly after admission to the hospital and reported significantly lower
than control levels of plasma Mg. Nath and co-workers (20) reported low Mg levels the 1st week after infarction that fell further the 2nd week. Brown et al. (21) and Hyatt et al. (22) who reported no such decreases did not specify when in the course of the hospitalization for infarction the blood samples had been drawn. That these differences may be due to differences in time of testing after the ischemic event, as suggested by Lossnitzer (23), is supported by experimental findings. Nath et al. (20) reported that 1 hr after experimental myocardial infarction in dogs, serum Mg levels dropped markedly. Blood drawn 24 and 48 hr after the infarction had normal levels of serum Mg. Clark and associates (24) and Cummings (3) drew blood 8 to 11 hr after coronary ligation, at the time the ectopic rhythm was established (and when magnesium was leaving the heart) and found elevated plasma Mg. The elevations in serum Mg after repeated bleeding of rats, withdrawing up to 40% of total blood as reported by Goldsmith et al. (25) may well have been derived from tissue stores. This is suggested also by the lower myocardial Mg in dogs with hemorrhagic hypotension (9).

Protection against anoxia; ischemia by magnesium

**Laboratory models.** There is laboratory evidence that magnesium salts protect against hypoxic damage to the heart (Tables 3A–C). Harris et al. (26) first demonstrated that either the sulfate or chloride of magnesium, given intravenously at a dosage of 1 mEq/liter suppressed the tachycardia and ectopic rhythm that had been caused by coronary ligation in 46 and 70% of the test dogs, respectively (Table 3A). Clark and Cummings (27) found that each of three successive infusions of MgSO4 corrected the multifocal ventricular tachycardia caused by coronary ligation (B. B. Clark and J. R. Cummings, personal communication). Carden and Steinhaus (28) then reported that Locke-Ringer solution lacking magnesium ex-

---

### TABLE 3Aa

<table>
<thead>
<tr>
<th>Model and reference</th>
<th>Magnesium salts</th>
<th>Parameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dogs</td>
<td>MgSO4 or MgCl2</td>
<td>Duration of suppression of the ectopic rate to ½ control rate.</td>
</tr>
<tr>
<td>Harris et al. (26)</td>
<td>1 mEq/liter, iv</td>
<td>MgSO4: successful in 5 of 11 dogs (46%); MgCl2: successful in 9 of 13 dogs (70%)</td>
</tr>
<tr>
<td>Dogs Cummings (personal communication)</td>
<td>MgSO4: 100 mg/kg in 20 ml H2O, iv</td>
<td>Conversion of ventricular tachycardia to sinus rhythm</td>
</tr>
<tr>
<td>Dogs Carden and Steinhaus (28)</td>
<td>Locke-Ringer solutionb Mg (0.05 mEq) Mg (2.00 mEq) Mg (0.05 mEq) in 0.9% NaCl Mg (2.00 mEq) in 0.9% NaCl Locke-Ringer solutionb Mg (0.05 mEq) in 5% dextrosec</td>
<td>Protection against ventricular fibrillation No protectionb ¹Fibrillationc</td>
</tr>
<tr>
<td>Rabbits Weber et al. (30)</td>
<td>Mg + K aspartate iv (alone and in combination)</td>
<td>Protection against ECG changes</td>
</tr>
<tr>
<td>Rats Bajusz and Selye (29)</td>
<td>Mg or K chloride, oral pretreatment for 5 days preligation</td>
<td>Protection against cardiac necrosis (autopsy 14 days after ligation)</td>
</tr>
</tbody>
</table>

---

a Coronary ligation.  
b Ringer's solution without Mg.  
c Two milliequivalents Mg in 5% dextrose.
erted no effect on the ventricular fibrillation caused by coronary ligation, whereas the same solution, to which either 0.05 mEq or 2.0 mEq of Mg was added, exerted a protective effect. The same concentrations of Mg in 0.9% NaCl were similarly protective, as was 0.05% in 5% dextrose. (The larger concentration of Mg in the dextrose solution, however, actually increased fibrillation.) Bajusz and Selye (29) reported that oral administration of MgCl₂ or KCl for 5 days before coronary ligation protected rats against cardiac necrosis. Protection by Mg and K aspartates against hypoxia-induced electrocardiographic changes has been demonstrated by Weber et al. (30) in rabbits with ligated coronary arteries.

Lamarche et al. (31–33) found that iv Mg and K aspartates, but not the chloride salts, protected against ECG changes of anoxia in guinea pigs (Table 3B). Hochrein and Lossnitzer (34) tested only the aspartates in guinea pigs exposed to asphyxia and found that Mg and K aspartates, in combination, doubled the cardiac tolerance of anoxia. They found that the magnesium salt alone exerted a lesser degree of protection; the potassium salt alone was ineffective.

Studies with isolated hearts of rats, rabbits, and guinea pigs exposed to anoxic conditions have compared mixtures of Mg and K aspartate with Mg and K chloride (Table 3C). The aspartates exerted a greater protective effect than the chlorides against the ECG changes and reduction in systolic amplitude caused by anoxia (31–33, 35, 36). In these studies, the immediate effect of anoxia was to increase the rate of perfusion of the fluid (maintained under constant pressure) through the coronary arteries of hearts being perfused with the balanced perfusion fluid (containing Mg and KCl). Rosen and associates (35) showed that when Mg and K aspartates were substituted for the chlorides, there were much greater rates of flow through the coronaries, whether the perfusion fluid was anoxic or normally oxygenated. Possibly this was a reflection of the greater systolic amplitude of the hearts perfused with fluids containing the aspartates (Fig. 1).

The foregoing studies reported protection by the magnesium salts (with and without potassium) that do not seem to be predominantly a function of a substantial effect on coronary blood flow. This is not to negate the known coronary dilation produced by even relatively low concentration of MgCl₂ (37, 38). The demonstration by Scott et al. (39) of the effect on coronary arterial resistance exerted by slight ionic changes of the blood (within normal limits) shows that such increases in plasma K⁺ or Mg²⁺ actively dilate the coronary vascular bed. A comparable study with hearts subjected to coronary ligation should provide valuable clarification of some of the dynamics by which the magnesium salts protected against ischemic damage in the experimental models just discussed. Studies designed to demonstrate the pharmacologic cardiac effects of hypermagnesemia are not relevant, either to the cardiac-protection laboratory studies or more particularly to the accumulating clinical data.

**Clinical evidence. Epidemiologic findings.** Kobayashi (40) first demonstrated a relationship between vascular disease and the hardness of drinking water, showing that the death rate

<table>
<thead>
<tr>
<th>Model and reference</th>
<th>Magnesium salts</th>
<th>Parameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guinea pigs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lamarche et al. (31)</td>
<td>Mg + K aspartate, iv (alone and in combination)</td>
<td>Protection against ECG changes and against tachycardia</td>
</tr>
<tr>
<td>Lamarche et al. (33)</td>
<td>Mg or KCl</td>
<td>Not effective</td>
</tr>
<tr>
<td>Guinea pigs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hochrein and Lossnitzer (34)</td>
<td>Mg + K aspartate</td>
<td>Doubles cardiac tolerance of asphyxia (cardiac respiration)</td>
</tr>
<tr>
<td></td>
<td>K aspartate</td>
<td>No protection</td>
</tr>
<tr>
<td></td>
<td>Mg aspartate</td>
<td>Some protection (less than with combination)</td>
</tr>
<tr>
<td></td>
<td>Mg + K aspartate</td>
<td>Decreases loss of myocardial K</td>
</tr>
</tbody>
</table>

*In vivo hypoxia; asphyxia.
TABLE 3c

<table>
<thead>
<tr>
<th>Model and reference</th>
<th>Magnesium salts</th>
<th>Parameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rats and Rabbits</td>
<td>Mg + K aspartate</td>
<td>Increased coronary flow (of perfusion fluid)</td>
</tr>
<tr>
<td></td>
<td>Mg + K chloride</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mg + K aspartate (but not chloride)</td>
<td>Increased resistance to anoxia: 1. 3–7 times less reduction of systolic amplitude 2. Protection against ECG changes 3. Increased worktime</td>
</tr>
<tr>
<td>Guinea pigs</td>
<td>Mg + K aspartate</td>
<td>Negligible effect on coronary flow</td>
</tr>
<tr>
<td>Lamarche and Royer</td>
<td></td>
<td>Protection against anoxia: 1. Protection against ECG changes 2. 35% prolongation of time to produce 75% reduction of systolic amplitude</td>
</tr>
<tr>
<td>Lamarche and Tapin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mg + K aspartate (D-aspartate not L-aspartate)</td>
<td></td>
</tr>
<tr>
<td>Guinea pigs</td>
<td>Mg + K aspartate</td>
<td>Increased resistance to anoxia (increased time for amplitude of heart beat to decrease to 50% control)</td>
</tr>
<tr>
<td>Rosen et al. (35)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mg + K aspartate (1.0 mg/ml of Chenoweth solution) more effective than Mg + KCl at equivalent concentration</td>
<td>Coronal flow increased over perfused nonanoxic heart</td>
</tr>
<tr>
<td></td>
<td>Mg + KCl</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mg + K aspartate</td>
<td>Coronal flow increased in both nonanoxic and anoxic hearts</td>
</tr>
</tbody>
</table>

a In vitro hypoxia; anoxia (isolated heart).

from apoplexy in Japan was higher in soft water areas than where the water was hard. Schroeder (41–45) then correlated the death rates from hypertensive and arteriosclerotic heart disease in the states with the average hardness of drinking water and found an inverse correlation. This was particularly notable for white men of 45 to 64 years of age as regards coronary heart disease death rates. The scatter graph (Fig. 2) shows that, with few exceptions, the states with the hardest drinking water had lower, and the states with the softest water had higher than average, death rates from ischemic heart disease. Further analysis of the states with the hardest and softest water reveals the markedly greater susceptibility to fatal heart attacks of white men aged 45 to 64, as compared with the total (age adjusted) male population (Fig. 3).

It is possible that this substantial difference may be caused by a racial difference in susceptibility to this disease. This is suggested by the figures from such southern states as Alabama and South Carolina where the white male versus total male coronary death rates are 433:176 and 619:217/100,000, respectively, and where the nonwhite population contributing to the total figures is predominantly black. Phillips and Burch (46) analyzed the literature in which the racial incidence of ischemic heart disease was given and evaluated their own data; they also found a significantly greater incidence of ischemic heart disease among white than black men. Bersohn (47) and Bersohn and Oelofse (48) also commented on the much greater susceptibility to ischemic heart disease of the African whites than the blacks and considered the higher serum Mg of the blacks a possibly significant factor.

Figure 3 also demonstrates that the more highly industrialized and more densely populated states tend to have higher coronary death rates. Average hardness figures hide major differences in hardness of water in different areas, particularly in large states.
rates than do the rural states. Comparison of death rates in three cities with hard, average, and soft water, illustrates strikingly the influence of the "water protective factor" in the high risk group (Fig. 4).

There has since been corroboration that the incidence of ischemic heart disease is higher in soft than in hard water areas (49–61). Calcium and magnesium have been considered as possibly protective factors, with both contributing to the hardness of the water. As calcium is usually present in larger amounts than is magnesium, there has been more attention paid to the possibility that it is calcium that is the protective "water factor" (50–55, 58, 59). Those who have had favorable experience in the treatment of ischemic heart disease with magnesium salts consider the hard water protective factor more likely to be magnesium than calcium (62–64), a position also taken by the present authors and demonstrated graphically (Fig. 5 (64a, 64b)) by Marier (65). Allen (49) has recently completed an exhaustive correlation of age and sex-specific death rates in municipalities in Ontario by total water hardness and by the calcium and magnesium components. His mathematical computations suggest that the protective effect of hard water is due to the magnesium component. In terms of percentage variation in death rates, he found that magnesium was more effective than total hardness, which in turn was more effective than calcium in favorably influencing the rate of sudden deaths from ischemic heart disease (Fig. 6). Allen's (49) decision to separate coroner-certified coronary deaths from total cardiovascular deaths, which revealed magnesium to be the most significant factor, was based on the observations of Crawford and Crawford (54) and of Anderson et al. (50). These investigators (50, 54) had observed that the incidence of sudden death from ischemic heart disease is notably higher in soft than in hard water areas.

---

**FIG. 1.** Protection against anoxia by magnesium and potassium aspartate solution (isolated guinea pig heart in Chenoweth (modified Locke-Ringer solution; J. Lab. Clin. Med. 31: 600, 1946)). Adapted from (35).

**FIG. 2.** Correlation of coronary heart disease death rates (1950) of white men 45 to 64 years of age with hardness of water by states in the United States. Adapted from (41).
extensive study clearly confirmed the conclusions of Anderson et al. (50).

Anderson and his associates (50) suggested that there is something in hard water that specifically protects against fatal cardiac arrhythmia arising shortly after a myocardial infarction. Bajusz (67) had earlier called attention to the possibility that it might be the magnesium in hard water that protects the myocardial cell against the insult caused by ischemia, as well as improving its ability to resist potentially cardiotoxic agents. When he first noted the relationship between water hardness and cardiovascular mortality, Schroeder (43, 44) pointed out that in cities with higher and lower coronary heart disease death rates for 45- to 64-year-old white men, the...
magnesium content of the water was 4:16, respectively. He and his co-workers (68) later concluded, on the basis of their own extensive analyses as well as from indirect evidence (69), that a good argument could be made for the existence of magnesium deficiency in the United States. They accepted as likely that diets high in calories and low in magnesium are atherogenic. They questioned, however, whether the amount of magnesium provided by hard water is sufficient to serve as the only protective factor against deaths from cardiovascular disease. Goldsmith (70) and Hankin and Goldsmith and Margen (71) have calculated that 12% of the daily Mg intake is derived from water. Among those using hard water only, as much as 18% of the Mg intake was from water (70), an amount that may well be critical.

The findings of Crawford and Crawford (54) that men under 40, who were living in a soft water area and who had died in accidents, had lower coronary magnesium levels and greater evidence of prior myocardial disease than did comparable men from a hard water area (Fig. 7) support the contention that lower magnesium levels are related to clinical ischemic heart disease. The higher coronary magnesium levels in the older age groups were postulated by the authors to have been caused by deposition of mineral deposits (Mg as well as Ca) in established coronary lesions. That life-long exposure to soft water is not necessary for higher death rates to be manifest is indicated by the evidence that softening previously hard water resulted in significantly elevated death rates from cardiovascular diseases from those in the community before the hard drinking water had been softened (52, 58, 59).

The question as to what it is in hard water that affords protection against both the development of coronary arteriosclerosis and the sudden death following an infarction is still controversial. The only definitive experimental study of the effect of calcium and magnesium in drinking water (on development of atherosclerosis) is that reported by Neal and Neal (72). They found that rabbits on an atherogenic diet that were given hard water to drink had less arterial damage than did those given distilled water. Addition to the distilled water of magnesium but not calcium completely protected against arteriosclerosis.4

The preponderance of direct and indirect evidence also favors magnesium as the myocardial protective factor. Firstly, magnesium deficit is known to cause functional and structural cardiovascular damage, including early mitochondrial and sarcosomal damage (73–78) and frank myocardial necrosis and calcification (75, 76, 79–98). Secondly, Mg deficiency sensitizes animals to myocardial necrosis produced in a number of laboratory models (Table 4), including those of dietary imbalances, stress, and drugs (85, 87–89), and accelerates the development of cardiac necrosis in hamsters genetically predisposed to cardiomyopathy (98). Furthermore, magnesium deficiency increases susceptible.

![FIG. 7. Coronary magnesium in accident cases of men under 60 years of age in Glasgow and London. Reprinted with permission of the publisher (54).](image-url)
bility to digitalis toxicity (23, 99–104), as hypomagnesemia has been reported in patients with digitalis toxicity (99, 100, 105), and magnesium is useful in countering digitalis-induced arrhythmias (100, 102, 106–110) and has protected against the cardiac necroses of the above experimental models (85, 86, 90, 96, 98, 111–121).

Calcium administration, in contrast, intensifies acute and chronic manifestations of Mg deficiency (122–128) and increases the cardiovascular damage caused by atherogenic- and infarction-producing diets (120–126, 128–133) or by cardiotoxic agents (85, 90, 96, 134). Lehr and Krukowski (114, 135) have postulated that hypercalcemia-inducing agents may exert their damaging effects on the cardiovascular system via induction or intensification of magnesium deficiency. Excess of adrenergic catecholamines may cause cardiac necrosis because they induce an adverse Ca/Mg ratio within the myocardium. Lehr et al. (134, 136, 137) demonstrated that these drugs cause an elevation in myocardial Ca and a drop in myocardial Mg within 3 hr that is maximal by 24 hr (Table 5). They considered this early electrolyte shift to play a contributory role in the initiation of dysfunction and morphologic alterations, and suggested that administration of MgCl₂ might correct the cellular depletion, thereby protecting against catecholamine injury. Fleckenstein et al. (113, 138, 139) have demonstrated that large doses of catecholamines cause not only an excessive Ca influx but also a dangerous fall in high-energy phosphate content of heart muscle prior to development of necrosis. Ca-antagonistic compounds and MgCl₂ protect against the excessive Ca-uptake and greatly diminish the structural damage (138, 140).

The thesis of Covino and Hegnauer (141) further negates calcium as a protective factor. They suggested that small increases in intracellular Ca²⁺ are associated with augmentation of cellular excitability, thereby contributing to the development of ventricular arrhythmia. Commenting on this postulate, Cummings (3) observed that the slightly reduced plasma Ca²⁺ at the time the plasma Mg²⁺ was sharply elevated (after coronary ligation) may have been caused by a shift of Ca from plasma to myocardium. That such an early elevation of myocardial Ca does, in fact, take place as myocardial Mg drops has been demonstrated both in experimental models of myocardial infarction and in human victims (1, 2).

Dietzman et al. (142) demonstrated that a continuous infusion of CaCl₂ to dogs caused myocardial hyperexcitability with an increased propensity toward appearance of ventricular ectopic beats. Fukuda (143) has demonstrated that Ca excess in Ringer's solution resulted in multiple firing of the frog's ventricle in response to a single stimulus. The more physiologic studies of Haddy and Scott et al. (39, 144–146) have shown that only slight changes in plasma Ca/Mg concentrations affect coronary resistance, relative hypercalcemia causing coronary constriction (particularly in the presence of hypomagnesemia), and relative hypermagnesemia causing coronary vasodilation (Fig. 8).

**Use of magnesium in treatment of cardiac ischemia.** Zwilling (110) first reported in 1935 the efficacy of intravenous MgSO₄ in countering cardiac arrhythmia of digitalis toxicity. Having demonstrated that MgSO₄ has

<table>
<thead>
<tr>
<th>Injection</th>
<th>Calcium</th>
<th>Magnesium</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>3</td>
</tr>
<tr>
<td>Isoproterenol</td>
<td>2.8</td>
<td>3.8</td>
</tr>
<tr>
<td>Phenylephrine</td>
<td>1.7</td>
<td>2.5</td>
</tr>
<tr>
<td>Epinephrine</td>
<td>1.7</td>
<td>2.1</td>
</tr>
</tbody>
</table>

*Adapted from Lehr et al. (134, 136, 137).
1.0 1.5 INFUSION RATE.

mI/mb of isotonic solutions I

SEELIG AND HEGGTVEIT

FIG. 8. Influence of Mg2+, K+, Na+ and Ca2+ on coronary resistance of in situ dog hearts at blood flow rates of 96 to 100 ml/min. Adapted from (39).

mI, mg/mb

According to a study by Elek and Katz (147), Mg was recommended for its use in 1942 in paroxysmal tachycardias associated with myocardial ischemia. They noted that Mg would be particularly suitable because it diminishes cardiac ischemia, which is known to maintain ectopic rhythms. Referring to the use of MgCl2 by Seekles et al. in 1930 (148) to prevent cardiac arrhythmias caused by CaCl2 (treatment of cows with milk fever or grass staggers, which was shown soon after to be a Mg-deficiency syndrome (83, 149)), Boyd and Scherf (150) confirmed the efficacy of MgSO4 therapy in paroxysmal tachycardia. Szekely (151) pointed out that patients whose arrhythmias responded best to Mg usually had advanced heart disease with congestive heart failure. Nonetheless, the use of Mg in ischemic heart disease has been slow to gain acceptance, particularly in North America. Favorable results have been reported from the Southern Hemisphere (64, 152–161), from both Eastern (121, 162, 163) and Western Europe (23, 31, 106, 164–177), and in Great Britain (19, 63, 178–183). The reports have been predominantly based on noncontrolled clinical trials of the use of several Mg preparations, sometimes in connection with other agents such as heparin (154, 159) and hyaluronidase (177) that complicate interpretation of results.

The first such report (in 1952) was that of Hoffman and Siegel from Germany (184), who reported excellent results in terms of reduced incidence of anginal attacks during treatment of their coronary angina patients with an oral preparation of Mg nicotinate and thiosulfate. Malkiel-Shapiro (154) and he and his co-workers (155, 156) have reported remarkably good results with MgSO4 in the treatment of patients during an acute attack of coronary thrombosis. They reported a low death rate of 1 in 64 in their patients with myocardial infarct so treated. For acute myocardial infarction, in addition to the usual supportive therapy, they generally inject MgSO4 iv or im (0.5 ml of 50% solution) immediately, 12 to 24 hr later, and then 1 ml im the next day and every 2 to 5 days thereafter until discharge. They maintain patients convalescing from an infarct and those with chronic angina pectoris by injecting either 0.5 ml of the MgSO4 im solution at 7-day intervals over an indefinite period or larger doses, given more frequently in intermittent courses (154). Parsons et al. (159) reported only 1 death in 33 cases of infarction. Perlia (162), in 1956, and more recently Savenkov and associates (163) also reported striking subjective improvement in over 90% and 79% of their coronary patients in response to iv MgSO4 (162) or to parenteral and oral use of magnesium adipinate and nicotinate (163).

The use of Mg and potassium aspartate, other organic salt, or chloride alone, or as part of a "polarizing solution" (containing glucose and insulin) has been reported by many German and French investigators to have improved significantly the chances of survival of victims of acute myocardial infarction (106, 165, 168–174). Prompt iv administration of Mg and K aspartate solution repeated daily (in doses as high as 4 to 5 g/day during the 1st week of hospitalization, with substitution thereafter of oral treatment) has been reported by Niener and Blumberger (172) to have relieved postinfarction pain and to have markedly improved the rate of survival. Also reported is the long-term efficacy of oral Mg and K aspartates in patients with chronic ischemic heart disease, either after an acute infarction or in patients with histories of coronary insufficiency (164, 170–173). Iontophoretic use of Mg2+ and K+ has also been described as helpful in the treatment of cardiac ischemia (166, 167). Thurnherr and Koch (177) reported that 90% of 156 patients with coronary insufficiency responded both subjectively (pain) and objectively (exercise tolerance) to injection with a combination of Mg levulinate and hyaluronidase. This study was controlled and injections of physiological saline served as the placebo.
MAGNESIUM INTERRELATIONSHIPS IN HEART DISEASE

Mechanisms of magnesium effects in ischemic heart disease.

Blood lipids. A commonly cited explanation for the clinical efficacy of magnesium relates to its effect on the blood. Clinicians from the British Commonwealth (64, 154–158, 161) and Russia (163) have reported that magnesium therapy of patients with ischemic heart disease is associated with decreased \( \beta \)-lipoproteins, increased \( \alpha \)-lipoproteins, and increased lecithin/cholesterol ratio, or a drop in serum cholesterol. There has not been agreement, however, that magnesium deficiency (as expressed by low plasma Mg levels) is necessarily correlated with lipemia in cardiovascular disease patients (21, 22, 185–187). Some insight into discrepancies in clinical results can be obtained from animal studies (Tables 6, 7). Depending on the nature of the fat given and the degree of the Mg deficiency, the serum cholesterol rose, was unchanged, or showed an increase in esterification (103, 122, 132, 188). Correction of the magnesium deficit has protected against cardio-

### TABLE 6
Effect of high and low saturated and unsaturated fat intakes and of magnesium on serum lipids in rats

<table>
<thead>
<tr>
<th>Dietary fatb</th>
<th>Serum magnesium, mg/100 ml</th>
<th>Serum cholesterol, mg/100 ml</th>
<th>Serum lipoproteins</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Satuated</td>
<td>Unsatuated</td>
<td>Satuated</td>
</tr>
<tr>
<td>Low fat intake, 5%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low magnesium</td>
<td>1.08</td>
<td>1.25</td>
<td>105</td>
</tr>
<tr>
<td>Moderate magnesium</td>
<td>2.21</td>
<td>2.03</td>
<td>99</td>
</tr>
<tr>
<td>High magnesium</td>
<td>2.56</td>
<td>1.91</td>
<td>83</td>
</tr>
<tr>
<td>High fat intake, 20%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low magnesium</td>
<td>1.51</td>
<td>0.96</td>
<td>115</td>
</tr>
<tr>
<td>Moderate magnesium</td>
<td>1.89</td>
<td>1.99</td>
<td>113</td>
</tr>
<tr>
<td>High magnesium</td>
<td>2.09</td>
<td>1.95</td>
<td>97</td>
</tr>
</tbody>
</table>

a Adapted from (189). Low magnesium = 24 mg/100 ml; moderate magnesium = 96 mg/100 ml; high magnesium = 192 mg/100 ml.
b Dietary fat: saturated: hydrogenated cottonseed oil; unsaturated: corn oil.

### TABLE 7
Lipids in experimental magnesium deficiency in dogs

<table>
<thead>
<tr>
<th>Mg intake</th>
<th>Fat intake</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.08% of diet</td>
<td>Butter fat (8% of diet)</td>
<td>↑Percent esterified cholesterol, ↑ Fatty acids, No change in total serum lipids, Kruse et al. (188)</td>
</tr>
<tr>
<td>0</td>
<td>Corn oil (9% of diet)</td>
<td>No change in blood cholesterol, Vitale et al. (103)</td>
</tr>
<tr>
<td>80 ppm</td>
<td>Animal fat (20% of diet)</td>
<td>↑ Aortic lesions, ↑ Serum cholesterol, Bunce et al. (122)</td>
</tr>
<tr>
<td>180 ppm</td>
<td>Animal fat (20% of diet)</td>
<td>No aortic lesions, ↑ Serum cholesterol, Sos et al. (131–133)</td>
</tr>
<tr>
<td>0</td>
<td>Animal fat Cardiopathogenic</td>
<td>↑ Serum cholesterol, Sos et al. (131–133)</td>
</tr>
<tr>
<td>(Also free of K, high in vitamin D; Ca, PO4, protein)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
vascular lesions of several species of animals on atherogenic Mg-deficient diets without a consistent effect on serum lipids (72, 104, 122, 128, 189–193). Except for a series of studies that showed Mg supplementation to lower serum cholesterol of milk-fed rats (194–196), and another that showed no effect on either cardiovascular or serum lipids of rabbits on atherogenic diets (197), administration of magnesium changed the distribution of lipid components somewhat or even raised the levels (72, 104, 128, 189, 193). Nakamura et al. (190) found that for a notable effect on aortic deposition of lipids and serum lipids, substantial and long-term Mg supplementation is necessary.

Fibrinolysis/coagulation. The efficacy of magnesium in ischemic heart disease has been attributed to its antithrombotic activity, both enhancement of fibrinolysis and inhibition of coagulation being considered as mediating mechanisms. Substantially increased fibrinolytic activity of the blood of cardiac ischemia patients on Mg therapy has been reported by Parsons et al. (159, 160). This observation recalls the explanation of the efficacy of the earlier use of Mg in prevention of postoperative thrombosis (198, 199) and in treatment of peripheral thrombotic disease (200, 201). The antithrombotic effect of magnesium has also been attributed to stabilization of platelet membranes (200, 202) and to inhibition of platelet aggregation (19, 183, 203, 204). Supportive of the platelet membrane theory is recent work that has shown that Mg is necessary to maintain the disc shape of platelets (205). Addition of MgCl₂ to fresh human blood, under conditions that maintained electrolytes and enzyme systems as nearly normal as possible, resulted in reduction in the size and number of platelet clumps and an increase in the number of discrete platelets (183). Hughes and Tonk’s (19) observations that rabbits with intravascular coagulation (induced by mineralocorticoid and monobasic sodium phosphate) have a 40% reduction of plasma Mg suggested to them that the subnormal Mg plasma levels of their patients with myocardial infarcts might be causally related to their enhanced platelet aggregation. Durlach’s (203) Mg-deficient patient with hypercoagulability of the blood and phlebothrombosis, who improved on oral administration of large doses of Mg (Mg lactate, 4.5 g/day) further demonstrates the interrelation between depression of Mg and increased tendency toward thrombosis. That the estrogen-induced hypercoagulability of the blood may also be mediated in part by decreased serum Mg has been suggested by Goldsmith et al. (25, 206–209). They have shown that estrogen oral contraceptives lower serum magnesium levels both in women (206, 207, 209) and in rats (25, 206, 208).

The antagonism of magnesium for calcium for clotting factors (210), even at concentrations produced after oral administration (182), has been considered another explanation of its anticoagulant activity (178, 182, 210, 211). A single oral dose has produced a delay in thrombin generation, lasting for up to 6 hr, in patients with ischemic heart disease (178, 182).

Stevenson and Yoder (212) have recently shown that Mg deficiency in calves and rats caused shortened partial thromboplastin time and thrombin clotting time but no significant changes in platelet aggregation or prothrombin time. Szelenyi et al. (213, 214) demonstrated that the hypercoagulability of blood, elicited in rats by atherogenic diets rich in animal fats and vitamin D₃, could be repressed by oral or intravenous administration of MgCl₂ in acute and long-term experiments. Five times the normal magnesium requirements, added to this diet, prevented the accelerated clotting of blood seen in animals that were given the fatty diet but with less magnesium. The magnesium supplementation normalized the coagulation time and prothrombin consumption times in both rats (Fig. 9) and dogs (Fig. 10) on the high fat diets. These investigators suggest that magnesium influences thrombosis: 1) by interfering with intravascular coagulation through its competition with calcium and by stabilizing fibrinogen and the platelets, 2) by promoting fibrinolysis, and 3) by causing vasodilatation.

A modification of this diet (poor also in Mg, K, and Cl) has been used by Sos and Rigo et al. (118, 120, 130–132) to produce myocardial infarction in several animal species. High Mg intake prevented the cardiac lesions (118–121, 133).

High intakes of vitamin D₃ (215–219) or fat (189, 193, 220–223) have been shown to increase magnesium requirements markedly and to intensify damage caused by magnesium deficiency, a possible explanation of the high
dosage of magnesium required for favorable effects in the above study (213). That this observation has clinical relevance is suggested by the tendency of people in the Occident to consume too much fat and by the evidence that vitamin D₃ intake, too, may be excessive in some of those who drink fortified milk (224–226), whereas the Occidental diet tends to be low in magnesium (68, 69). This combination of dietary imbalances may produce sufficient magnesium deficiency to contribute to the cardiovascular disease problems of the Western world (1, 2, 69, 227, 228).

Magnesium and myocardial metabolism

Magnesium has a pivotal position in normal physiology, participating in many enzyme systems. The evidence as to its importance in maintaining mitochondrial integrity and in retaining myocardial potassium has been considered elsewhere (1). Magnesium is involved in normal mitochondrial contraction with formation of the compact Mg-ATP complex and is involved in the electron transport system (Fig. 11). With depletion of cardiac magnesium, whether from ischemia or cardiotoxic drugs, mitochondrial swelling progresses to disorganization and disruption (Fig. 12).

The importance of magnesium and potassium in myocardial aerobic metabolism has been stressed by Laborit (168), who studied the effects of the aspartates of these cations in experimental cardiac anoxia (supra vide), and by Nieper and Blumberger (172) who introduced the use of the substances in the clinic. The latter investigators consider the intracellular metabolic effects of magnesium far more
important in the treatment of cardiac ischemia than its antithrombotic effects. They have pointed out that Parsons et al. (160), who stressed the importance of the activation of fibrinolysis by magnesium, commented on the striking improvement in mortality rates of patients with infarctions on MgSO₄ as compared with the one-third fatality rate when routine anticoagulant therapy was used (the year before institution of the magnesium therapeutic regimen). Nieper and Blumberger (172) recommend use of the magnesium and potassium aspartates on the grounds that better penetration by Mg and K of the cell membrane may thereby be provided. They have reported that such treatment has corrected the abnormal oxidative metabolism of the ischemic or digitalis-treated heart, as measured by an increase to a more normal pyruvic acid/lactic acid ratio and by elevation of α-ketoglutaric acid (an indicator of activation of the tricarboxylic acid cycle). Simon (175) considers all of the cited mechanisms to be operative in the favorable effects of Mg in the treatment of myocardial infarction, a judgment in which the present authors concur.

Concluding comments

The usefulness of magnesium in ischemic heart disease is probably best explained by its metabolic effects at the cellular level, but its interrelations with lipid metabolism and coagulation-fibrinolytic mechanisms are probably also significant. It 1) counteracts the adverse effects of excessive intracellular calcium, 2) plays an important role in retaining intracellular potassium, and 3) is important in maintaining the integrity of the subcellular structures. Its role in maintaining normal rhythmicity of the heart in the face of an ischemic insult may well explain the difference in sudden cardiac death rates in hard and soft water areas. Therapeutic use of magnesium in acute ischemic heart disease may well be justified. The long-term prophylactic use of magnesium for the inhibition of atherogenesis or the prevention of acute ischemic attack, or both, requires further study.

References

6. JENNINGS, R. B. Symposium on the prehospital phase of acute myocardial infarction, Part II—Early Phase of Myocardial Ischemic
MAGNESIUM INTERRELATIONSHIPS IN HEART DISEASE

73

74 SEELIG AND HEGGTVEIT

MAGNESIUM INTERRELATIONSHIPS IN HEART DISEASE


MAGNESIUM INTERRELATIONSHIPS IN HEART DISEASE


148. SEEKLES, L., B. SIOLLEMA AND J. C. VANDERKAY. Tydschr. v. diergenesk 57: 1229, 1930 (cited by Boyd and Scherf (150)).


166. Kohler, U. Modern therapy of angina pectoris and prevention of myocardial infarction by...


188. KRUSE, H. D., E. R. ORENT AND E. V. MCCOLLUM. Studies on magnesium deficiency in animals. III. Chemical changes in the blood following magnesium deprivation. J. Biol. Chem 100: 603, 1933.


MAGNESIUM INTERRELATIONSHIPS IN HEART DISEASE


